REPRISE Trial - Tolvaptan in CKD - Visual Abstract Does tolvaptan slow the progression of autosomal dominant polycystic kidney disease? Conclusions Tolvaptan, in a follow-up to the larger and longer Tempo 3:4 trial again slowed the progression of CKD in ADPKD, It also relieved some disease symptoms. https://www.nejm.org/doi/10.1056/NE #Tolvaptan #REPRISE #Trial #CKD #VisualAbstract #EBM #Nephrology
